Abstract:
Polypeptides of the formula: ##STR1## and the reduced linear form thereof, whereinX is H, Ala-Gly-, Ala-D-Ala, Gly-Gly-Gly-, acetyl or benzoyl;X.sub.4 is Arg or His;X.sub.8 is Trp or D-Trp;X.sub.14 is Cys or D-Cys,or a non-toxic acid addition salts thereof, inhibit the secretion of growth hormone, insulin and glucagon.
Abstract:
The pentapeptide: H-Tyr-Gly-Gly-Phe-Ser-OH, or a non-toxic salt thereof, exerts an analgesic effect in rats by injection into the lateral brain ventricle.
Abstract:
The polypeptide H-Tyr-Gly-Gly-Phe-Leu-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-OH, or a non-toxic salt thereof, exerts an analgesic effect in rats when injected into the lateral brain ventricle.
Abstract:
Somatostatin analogs which contain L-Arg.sup.4 -L-His.sup.5 amino acids residues in place of the normally present L-Lys.sup.4 -L-Asn.sup.5 residues are disclosed. Other modifications of somatostatin are also disclosed.These compounds inhibit the release of pituitary growth hormone, glucagon, and insulin.
Abstract:
The pentapeptide: H-Tyr-Gly-Gly-Phe-D-Lys-OH, or a non-toxic salt thereof, exerts an analgesic effect in rats by injection into the lateral brain ventricle.
Abstract:
Cyclized somatostatin analogues containing the Cys-Cys disulfide linkage, their pharmaceutically acceptable acid addition salts as well as their cyclic disulfhydryl precursors and intermediates therefor are disclosed. The cyclized analogues of somatostatin selectively reduce blood serum concentrations of growth hormone without materially affecting the concentrations of glucagon or insulin.
Abstract:
The tetradecapeptide Ala-Gly-Tyr-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Tyr-OH is described as well as novel intermediates used in the synthesis of such tetradecapeptide. This tetradecapeptide inhibits the release of growth hormone.
Abstract:
The growth hormone release inhibiting compound. ##EQU1## the protamine zinc, protamine aluminum and non-toxic acid addition salts thereof as well as the corresponding linear heptadecapeptide and intermediates therefore are herein described.
Abstract translation:生长激素释放抑制化合物。 H-Gly-Gly-Tyr-Ala-Gly-Cys-Lys-Asn-Phe- | S || | S | Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH 因此,本发明描述了鱼精蛋白铝及其无毒酸加成盐以及相应的线性十七肽和中间体。
Abstract:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
Abstract:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.